High expression of SMYD3 indicates poor survival outcome and promotes tumour progression through an IGF-1R/AKT/E2F-1 positive feedback loop in bladder cancerGuoliang Wang, Cheng Liu, Yi Huang et al.|Aging|2020Cited by 32
444P Efficacy and safety of sintilimab in combination with anlotinib plus metronomic chemotherapy in advanced triple-negative breast cancer (SPACE): Preliminary results of a single-arm, multicenter phase II trialHan Li, Zhenfeng Shi, Jing Huang et al.|Annals of Oncology|2023Cited by 1